Trial Profile
Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Reactive Protein (CRP), Calprotectin, Ustekinumab Through Levels and Antibodies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Acronyms SAFARI
- 23 Aug 2022 Status changed from recruiting to completed.
- 08 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
- 08 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.